Celldex SVP granted options on 95,000 shares

Celldex Therapeutics, Inc. reported that SVP of Corporate Affairs & Administration Sarah Cavanaugh received a grant of incentive stock options.

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. reported that SVP of Corporate Affairs & Administration Sarah Cavanaugh received a grant of incentive stock options. She was awarded options covering 95,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.

Following this grant, she holds derivative securities for 95,000 underlying shares. The options have a long-term vesting schedule: 25% vest on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the subsequent 12 quarters, and they expire on June 25, 2036.

Insider Trade Summary

Grant/Award: 95,000 shares

Grant/Award 1 txn

Insider Cavanaugh Sarah

Role SVP OF CORP AFFAIRS & ADMIN.

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	95,000	$0.00	$0.00

Holdings After Transaction: Incentive Stock Option (right to buy) — 95,000 contracts (Direct)

Footnotes (2)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. F2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Key Figures

Option grant size: 95,000 shares Exercise price: $34.09 per share Vesting cliff: 25% on June 25, 2027 +3 more

6 metrics

Option grant size 95,000 shares Incentive Stock Option covering common stock

Exercise price $34.09 per share Strike price of Incentive Stock Option

Vesting cliff 25% on June 25, 2027 Initial vesting of option grant

Remaining vesting period 12 quarters Equal quarterly vesting after June 25, 2027

Expiration date June 25, 2036 Option term end date

Post-grant derivative holdings 95,000 derivative shares Total underlying shares following transaction

Key Terms

Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vest, exercise price, +1 more

5 terms

Incentive Stock Option financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

vest financial

"25% vest on June 25, 2027 and the remainder vest quarterly over 12 quarters."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: 34.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-25T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex (CLDX) executive Sarah Cavanaugh report in this Form 4?

Sarah Cavanaugh reported receiving an incentive stock option grant. The award covers 95,000 shares of Celldex common stock, giving her the right to buy shares at a fixed exercise price of $34.09 per share in the future.

How many Celldex (CLDX) shares are covered by the new stock options?

The new grant covers options on 95,000 shares of Celldex common stock. These options are derivative securities, meaning they represent the right to purchase shares later rather than current share ownership today.

What is the exercise price of Sarah Cavanaugh’s Celldex (CLDX) stock options?

The options have an exercise price of $34.09 per share. This is the fixed price at which she can buy Celldex common stock once the options vest, regardless of the market price at that time.

When do the Celldex (CLDX) stock options granted to Sarah Cavanaugh vest?

The vesting schedule begins with 25% vesting on June 25, 2027. The remaining 75% then vest in equal quarterly installments over the following 12 quarters, gradually increasing the portion of options she can exercise.

When do Sarah Cavanaugh’s Celldex (CLDX) stock options expire?

The incentive stock options expire on June 25, 2036. After that expiration date, any unexercised options become worthless and can no longer be used to purchase Celldex common stock at the $34.09 exercise price.

Is this Celldex (CLDX) Form 4 an open-market stock purchase or a compensation grant?

This Form 4 reports a grant/award acquisition of incentive stock options, not an open-market share purchase. The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan as part of equity-based compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavanaugh Sarah

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP OF CORP AFFAIRS & ADMIN.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		95,000		06/25/2027(2)	06/25/2036	Common Stock	95,000	$0	95,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)